CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood’s Bet on the Gene-Editing Stock Dead Money?CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood’s Bet on the Gene-Editing Stock Dead Money?
CRISPR Therapeutics (NASDAQ: CRSP) is up only slightly more than 8% so far this year, well under the 27% return{...}